Johnson and Johnson reinvested in Inivata, which will use the series A funding to advance its cancer diagnostics platform through clinical studies.

UK-based oncology genomics technology developer Inivata closed a £31.5m ($45m) series A round today featuring Johnson & Johnson Innovation – JJDC, the corporate venturing arm of healthcare group Johnson & Johnson.

The round also included university venturing fund Imperial Innovations, which invested $14.3m, the Cambridge University-affiliated Cambridge Innovation Capital and investment trust Woodford Patient Capital Trust.

Inivata is working on oncological diagnostics technology that uses a blood test for circulating tumour DNA analysis that can reveal the presence of cancer…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?